GlassScriptPhysician profile
Spencer Borns
NPI 1215387907
$4,272.79
in general payments reported to CMS, 2019-2025
32 companies · $2,118 in 2025
The $2,118 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $277 · 2022: $522 · 2023: $786 · 2024: $570 · 2025: $2,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,533 · Travel and Lodging: $731 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,533.16 |
| Travel and Lodging | $731.24 |
| Education | $209.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,644.43 | 2023-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $617.93 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Jazz Pharmaceuticals INC. | $270.03 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $236.22 | 2022-2025 | Dupixent |
| Amgen INC. | $165.01 | 2021-2024 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.34 | 2022-2023 | Ofev |
| Janssen Pharmaceuticals, INC | $133.40 | 2021-2023 | Xarelto |
| Pfizer INC. | $121.81 | 2021-2022 | |
| Insmed, INC. | $94.77 | 2023-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $93.03 | 2022-2025 | Wakix |
| Grifols USA, LLC | $87.74 | 2022-2023 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $76.70 | 2022-2023 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $69.27 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $67.03 | 2025 | Winrevair |
| Electromed, INC. | $61.51 | 2023-2025 | Smartvest |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $55.65 | 2022-2024 | Opsumit, Uptravi |
| Axsome Therapeutics, INC. | $32.04 | 2023-2025 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $30.19 | 2023 | Glassia |
| Mylan Specialty L.P. | $29.91 | 2023 | Yupelri |
| Zoll Respicardia, INC. | $26.08 | 2023 | Remede System |
| Ani Pharmaceuticals, INC. | $25.75 | 2024 | Purified Cortrophin Gel |
| Ucb, INC. | $20.07 | 2021 | |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Verona Pharma, INC. | $19.18 | 2025 | Ohtuvayre |
| Genzyme Corporation | $19.04 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.07 | 2022 | |
| Lilly USA, LLC | $14.88 | 2025 | Mounjaro |
| Avadel Cns Pharmaceuticals, LLC | $14.66 | 2025 | Lumryz |
| Novartis Pharmaceuticals Corporation | $14.06 | 2021 | |
| Viatris Specialty LLC | $13.91 | 2025 | Yupelri |
| Genentech USA, INC. | $12.87 | 2023 | Xolair |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Borns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.